Trial Profile
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs Denintuzumab mafodotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seagen
- 05 Jul 2018 Status changed from active, no longer recruiting to discontinued.
- 08 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 29 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Apr 2018.